Clinical Trials
66 trialsTrial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
TRICAR
Queen Mary University of London
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
M.D. Anderson Cancer Center
PharmTRT
Hospices Civils de Lyon
Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors
CHU de Reims
A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022
Suez Canal University
Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022
Suez Canal University
The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022
Suez Canal University
IMMUNORARE5
Hospices Civils de Lyon
SAFRO2202
Société Algérienne de Formation et de Recherche en Oncologie
LIFENETS
Sunnybrook Health Sciences Centre
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
P-PRRT
CHU de Quebec-Universite Laval
EVENET
AC Camargo Cancer Center
BANN
University Medical Center Groningen
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
SCRI Development Innovations, LLC
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Clinical and Pathologic Studies in Neuroendocrine Tumors
Stanford University
RGS-GEP-NET
European Institute of Oncology
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
University of Alabama at Birmingham
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
18F-FDOPA PET in Neuroendocrine Tumours
British Columbia Cancer Agency
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
University of Chicago
GA-68
University of Iowa
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
British Columbia Cancer Agency
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
University of Iowa
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
CHARRT
King's College Hospital NHS Trust
SwissNET
Insel Gruppe AG, University Hospital Bern
Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
M.D. Anderson Cancer Center
DOTA-TOC
University of California, San Francisco
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Massachusetts General Hospital
Endoscopic Treatment of Bronchial Carcinoid Tumors
Centre Hospitalier Universitaire de Saint Etienne
A Study of Axitinib in Advanced Carcinoid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)
CHU de Reims
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
Western University, Canada
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Stanford University
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Icahn School of Medicine at Mount Sinai